Polygon Therapeutics Overview
- Year Founded
-
2021
- Status
-
Private
- Employees
-
8
- Latest Deal Type
-
Accelerator/Inc
- Investors
-
5
Polygon Therapeutics General Information
Description
Operator of a biotech company intended for the treatment of cardiovascular diseases. The company provides a therapeutic development program to improve cardiovascular disease care and mitigate the damage inflicted on the heart, enabling the healthcare industry to reduce the burden of cardiovascular diseases by providing early-stage treatment to patients.
Contact Information
Website
www.polygon.careCorporate Office
- 26 Rue Laffitie
- Levallois-Perret
- 75009 Paris
- France
Corporate Office
- 26 Rue Laffitie
- Levallois-Perret
- 75009 Paris
- France
Polygon Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Accelerator/Incubator | 17-Apr-2024 | Completed | Pre-Clinical Trials | |||
| 2. Seed Round | Completed | Startup | ||||
| 1. Accelerator/Incubator | 01-Jan-2022 | Completed | Startup |
Polygon Therapeutics Patents
Polygon Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2023381445-A1 | Anti-cd8 alpha depleting antibodies | Pending | 17-Nov-2022 | ||
| EP-4619436-A1 | Anti-cd8 alpha depleting antibodies | Pending | 17-Nov-2022 | ||
| US-12522659-B2 | Anti-cd8 alpha depleting antibodies | Active | 17-Nov-2022 | ||
| US-20250277036-A1 | Anti-cd8 alpha depleting antibodies | Active | 17-Nov-2022 | ||
| US-20260098091-A1 | Anti-cd8 alpha depleting antibodies | Pending | 17-Nov-2022 | C07K16/2815 |
Polygon Therapeutics Signals
Polygon Therapeutics Investors (5)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| EIT Health | Accelerator/Incubator | |||
| Agoranov | Accelerator/Incubator | |||
| Aloe Private Equity | PE/Buyout | Minority | ||
| Audacia | Growth/Expansion | Minority | ||
| Sorbonne Venture | Venture Capital | Minority |
Polygon Therapeutics FAQs
-
When was Polygon Therapeutics founded?
Polygon Therapeutics was founded in 2021.
-
Where is Polygon Therapeutics headquartered?
Polygon Therapeutics is headquartered in Paris, France.
-
What is the size of Polygon Therapeutics?
Polygon Therapeutics has 8 total employees.
-
What industry is Polygon Therapeutics in?
Polygon Therapeutics’s primary industry is Drug Discovery.
-
Is Polygon Therapeutics a private or public company?
Polygon Therapeutics is a Private company.
-
What is Polygon Therapeutics’s current revenue?
The current revenue for Polygon Therapeutics is .
-
How much funding has Polygon Therapeutics raised over time?
Polygon Therapeutics has raised $7.5M.
-
Who are Polygon Therapeutics’s investors?
EIT Health, Agoranov, Aloe Private Equity, Audacia, and Sorbonne Venture have invested in Polygon Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process